ADMA Biologics(ADMA) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for 2025 was $510 million, representing a 20% year-over-year growth [5][12] - Adjusted EBITDA reached $231 million, increasing 40% year-over-year [5][12] - Adjusted net income totaled $161 million, reflecting a 35% increase year-over-year [5][12] - Gross margin expanded to 57.4% from 51.5% in 2024, driven by Asceniv's contribution [12] Business Line Data and Key Metrics Changes - Asceniv achieved $363 million in net revenue for 2025, representing a 51% year-over-year growth [6] - The company expects a continued shift in product mix towards Asceniv, with a projected 70-30 split between Asceniv and Bivigam in 2025 [27] Market Data and Key Metrics Changes - The company anticipates total revenue to exceed $635 million in 2026, driven primarily by Asceniv utilization [15][43] - For 2027, total revenue is expected to exceed $775 million, with projections for 2029 to exceed $1.1 billion [15] Company Strategy and Development Direction - The company is focused on driving commercial execution, investing in a capital-efficient pipeline, and maintaining balance sheet discipline [10][11] - Strategic repositioning of the plasma collection network aims to enhance capital efficiency and secure long-term supply visibility [21][22] - The lead pipeline asset, SG-001, is expected to represent a significant long-term revenue opportunity, with a pre-IND package submission anticipated in 2026 [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position entering 2026, highlighting strong demand in the U.S. IG market and improved cash generation [20][22] - The integration of yield-enhanced production is expected to support meaningful gross margin growth and increasing earnings power [8][12] Other Important Information - The company announced a leadership transition with the appointment of Terry Kohler as the new CFO, following Brad Tade's retirement [10][18] - The company ended 2025 with $88 million in cash, excluding proceeds from the plasma center divestiture [14] Q&A Session Summary Question: Update on Asceniv's role in revenue guidance - Management confirmed Asceniv's growth of 51% year-over-year and expects continued growth in its product mix [27][29] Question: Update on third-party supply contracts for RSV plasma - Management reported that third-party supply agreements are performing well, with ongoing collection and testing of plasma [34][36] Question: Expected new centers and prescriber base growth in 2026 - Management indicated active outreach to about 300 immunologists and plans to expand prescriber base and institutions using Asceniv [41][43] Question: Timeline for McKesson's impact on receivables - Management expects to see McKesson's impact materialize in the latter half of the year, with ongoing efforts to normalize accounts receivable [45][46]